News | June 22, 2022
AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Bringing next-gen cannabinoid therapeutics to cancer patients
Atik Cameras launches ChemiMOS; A 9MP CMOS camera for scientific applications
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
Both manufacturing facilities are based out of Benguluru, India
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
Subscribe To Our Newsletter & Stay Updated
